Biocryst Pharmaceuticals price to book ratio BCRX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 56.6×; Feb 2021
10-year median: 14.3×
10-year range: 4.3× to 190×
Peer median: 5.6×

Biocryst Pharmaceuticals' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Feb 2021, at 56.6×.

On the days it had one over the last ten years, its median was 14.3×, from 4.3× in Feb 2018 to 190× in May 2020.

Price to book ratio over time

median 14.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	56.6×	40.6×	60.5×
2020	39.1×	7.5×	190×
2019	15.0×	12.0×	39.5×
2018	11.9×	4.3×	17.1×
2017	4.8×	4.4×	132×
2016	117×	2.0×	129×
2015	11.8×	7.9×	18.1×
2014	10.3×	8.3×	199×
2013	130×	6.2×	130×
2012	7.3×	4.2×	17.4×
2011	4.3×	2.8×	5.3×

Against its peers

Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
BCRXBiocryst Pharmaceuticals	n/m
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
MGTXMeiraGTx	4.1×
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
TECHBIO-TECHNE	5.4×
HALOHalozyme Therapeutics	99.3×
NBIXNeurocrine Biosciences	3.9×
EXELExelixis	8.7×
PLXProtalix BioTherapeutics	2.9×
Peer median	5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Biocryst Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.